Clinical Trial Update: The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating Fruquintinib with FOLFIRI/FOLFOX as second-line therapy for RAS-mutant metastatic colorectal cancer; efficacy and safety data not ye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• FOLFOX
• Fruquintinib (fruquintinib)

Snippet

Sponsor: Fudan University | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: UNKNOWN